NATIONAL INSTITUTES OF HEALTH

Ensysce Biosciences treated first group in PF614-MPAR-102 study, aiming for early interim data in 1Q 2025. PF614-MPAR received FDA Breakthrough Therapy designation, supported by a $14 million NIDA award. Ensysce targets reducing opioid abuse and overdose with its TAAP and MPAR platforms.

Study finds states with higher economic vulnerability and minoritized populations have fewer gynecological cancer trials per 100,000 persons, highlighting the need for efforts to address these disparities.

Streamlined kidney transplant evaluation reduced discrimination and medical mistrust among 820 candidates, with Black participants also reporting less perceived racism. However, Black participants showed decreased physician trust at follow-up, contrasting with unchanged trust among White participants.

POP Biotechnologies received $2.84M for developing a unique influenza vaccine using SNAP technology, aiming to address seasonal flu's unmet needs.

The global genomic testing market, valued at $14.52B in 2023, is projected to reach $32.95B by 2032, driven by innovations like CRISPR therapies, AI-driven tools, and long-read sequencing technologies. Major advancements include the first complete sequencing of the human Y chromosome and the deployment of portable sequencing devices globally. Investments in genomic research and precision medicine trials highlight the market's potential to transform healthcare through personalized treatments.

Women spend 25% more of their lives in poor health than men, yet are underrepresented in clinical trials, leading to a data gap affecting drug efficacy and safety. This underrepresentation is exacerbated by gender disparities among principal investigators and concerns over pregnancy and hormonal variability. Increased female participation and investment in women's health could boost the global economy by $1 trillion annually by 2040. New technologies and inclusive recruitment practices are essential for more equitable clinical trials.

Cognition Therapeutics completes Phase 2 SHIMMER study of CT1812 for mild-to-moderate dementia with Lewy bodies (DLB), expecting topline results in Dec 2024. CT1812, an orally delivered small molecule targeting sigma-2 receptor complex, aims to modify DLB progression. The study, supported by NIH with $30 million, involved 130 DLB patients. Cognition Therapeutics also advances Alzheimer's research, with CT1812 showing potential in slowing cognitive decline and improving brain connectivity. Financials show a net loss of $7 million in Q2 2024, with $28.5 million in cash to fund operations until Q2 2025.